Skip Ribbon Commands
Skip to main content
Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

​​Changes to medical policy on gonadotropin-releasing hormone agonist

January 5, 2023

​Effective January 2, 2023, Independence Blue Cross and Independence Administrators have updated their medical policy on gonadotropin-releasing hormone agonist (CamceviTM, Eligard®, Fensolvi®, Lupron Depot®).

Criteria and codes were updated in alignment with company-recognized drug compendia. The coverage positions were added/revised for the following HCPCS codes:

  • J1950: Coverage changed from Not Medically Necessary to Medically Necessary for Breast Cancer and Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer.
  • J1951 (Fensolvi): Coverage changed from Medically Necessary to Not Medically Necessary for endometriosis, uterine fibroids, and gender dysphoria.
  • J1952 (Camcevi): Coverage was added for Not Medically Necessary indications in the policy.

For more information, view policy #08.01.33h: Gonadotropin-Releasing Hormone Agonist (CamceviTM, Eligard®, Fensolvi®, Lupron Depot®), which was published on December 30, 2022.

This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.